Pharmafile Logo
Pharmafocus logo
Advanced Search

Onivyde

Showing 3 posts of 3 posts found.

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment

February 14, 2024
Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma

Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …

News
handshake-1910702_960_720

Merrimack sells off drug for $1 billion and cuts workforce by 80%

January 9, 2017
Sales and Marketing Onivyde, ipsen, merrimack

Ipsen has announced the agreement to acquire oncology assets from Merrimack Pharmaceuticals, most notably the pancreatic cancer drug Onivyde, in …

News
nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024